{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T01:29:09Z","timestamp":1786584549625,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373200"],"award-info":[{"award-number":["82373200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Fujian Provincial Natural Science Foundation of China","award":["2023J011253"],"award-info":[{"award-number":["2023J011253"]}]},{"name":"the National Clinical Key Specialty Construction Program, Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy","award":["2020Y2012"],"award-info":[{"award-number":["2020Y2012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"DOI":"10.1186\/s12903-026-08865-8","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:33:30Z","timestamp":1780965210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of schedule-modified oral capecitabine\/S-1 as maintenance therapy for stage N3 nasopharyngeal carcinoma after definitive chemoradiotherapy: a multicentre, single-arm phase II clinical trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiang","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingcan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaobin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caizhu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaojuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"8865_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"10192","key":"8865_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet (London England). 2019;394(10192):64\u201380.","journal-title":"Lancet (London England)"},{"issue":"5","key":"8865_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.oraloncology.2014.02.006","volume":"50","author":"SW Tsao","year":"2014","unstructured":"Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 2014;50(5):330\u20138.","journal-title":"Oral Oncol"},{"issue":"7","key":"8865_CR4","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.20.03237","volume":"39","author":"YP Chen","year":"2021","unstructured":"Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, et al. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021;39(7):840\u201359.","journal-title":"J Clin Oncol"},{"issue":"3","key":"8865_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ijrobp.2019.06.2549","volume":"105","author":"XS Sun","year":"2019","unstructured":"Sun XS, Liu SL, Luo MJ, Li XY, Chen QY, Guo SS, et al. The Association Between the Development of Radiation Therapy, Image Technology, and Chemotherapy, and the Survival of Patients With Nasopharyngeal Carcinoma: A Cohort Study From 1990 to 2012. Int J Radiat Oncol Biol Phys. 2019;105(3):581\u201390.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"8865_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.oraloncology.2013.06.003","volume":"50","author":"WT Ng","year":"2014","unstructured":"Ng WT, Yuen KT, Au KH, Chan OS, Lee AW. Staging of nasopharyngeal carcinoma\u2013the past, the present and the future. Oral Oncol. 2014;50(6):549\u201354.","journal-title":"Oral Oncol"},{"issue":"21","key":"8865_CR7","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/cncr.30198","volume":"122","author":"JJ Pan","year":"2016","unstructured":"Pan JJ, Ng WT, Zong JF, Lee SW, Choi HC, Chan LL, et al. Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC\/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122(21):3307\u201315.","journal-title":"Cancer"},{"issue":"3","key":"8865_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.radonc.2013.10.020","volume":"110","author":"X Sun","year":"2014","unstructured":"Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110(3):398\u2013403.","journal-title":"Radiother Oncol"},{"key":"8865_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.oraloncology.2019.09.029","volume":"98","author":"LR Wu","year":"2019","unstructured":"Wu LR, Zhang XM, Xie XD, Lu Y, Wu JF, He X. Validation of the 8th edition of AJCC\/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with 10-year follow-up. Oral Oncol. 2019;98:141\u20136.","journal-title":"Oral Oncol"},{"issue":"11","key":"8865_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509\u201320.","journal-title":"Lancet Oncol"},{"issue":"5","key":"8865_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamaoncol.2022.0122","volume":"8","author":"WZ Li","year":"2022","unstructured":"Li WZ, Lv X, Hu D, Lv SH, Liu GY, Liang H, et al. Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022;8(5):706\u201314.","journal-title":"JAMA Oncol"},{"issue":"10297","key":"8865_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","volume":"398","author":"YP Chen","year":"2021","unstructured":"Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398(10297):303\u201313.","journal-title":"Lancet"},{"issue":"12","key":"8865_CR13","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1001\/jamaoncol.2022.4656","volume":"8","author":"J Miao","year":"2022","unstructured":"Miao J, Wang L, Tan SH, Li JG, Yi J, Ong EHW, et al. Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2022;8(12):1776\u201385.","journal-title":"JAMA Oncol"},{"key":"8865_CR14","doi-asserted-by":"publisher","unstructured":"Zong J, Xu H, Chen B, Guo Q, Xu Y, Chen C et al. Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma. Radiat Oncol (London England) 2019;14(1):182. https:\/\/doi.org\/10.1186\/s13014-019-1387-9.","DOI":"10.1186\/s13014-019-1387-9"},{"key":"8865_CR15","doi-asserted-by":"publisher","first-page":"105313","DOI":"10.1016\/j.oraloncology.2021.105313","volume":"118","author":"J Zong","year":"2021","unstructured":"Zong J, Liu Y, Liang Q, Xu H, Chen B, Guo Q, et al. Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma. Oral Oncol. 2021;118:105313.","journal-title":"Oral Oncol"},{"issue":"4","key":"8865_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(18)30104-9","volume":"19","author":"LQ Tang","year":"2018","unstructured":"Tang LQ, Chen DP, Guo L, Mo HY, Huang Y, Guo SS, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(4):461\u201373.","journal-title":"Lancet Oncol"},{"issue":"12","key":"8865_CR17","doi-asserted-by":"publisher","first-page":"e2138470","DOI":"10.1001\/jamanetworkopen.2021.38470","volume":"4","author":"QN Tang","year":"2021","unstructured":"Tang QN, Liu LT, Qi B, Guo SS, Luo DH, Sun R, et al. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2021;4(12):e2138470.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"8865_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.radonc.2014.01.011","volume":"110","author":"S Lin","year":"2014","unstructured":"Lin S, Pan J, Han L, Guo Q, Hu C, Zong J, et al. Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin. Radiother Oncol. 2014;110(3):385\u20139.","journal-title":"Radiother Oncol"},{"issue":"8","key":"8865_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","volume":"7","author":"E Pasquier","year":"2010","unstructured":"Pasquier E, Kavallaris M, Andr\u00e9 N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7(8):455\u201365.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"8865_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","volume":"13","author":"G Bocci","year":"2016","unstructured":"Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016;13(11):659\u201373.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"8865_CR21","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/cas.70037","volume":"116","author":"YF Yu","year":"2025","unstructured":"Yu YF, Dai YQ, Zhang ZK, Lu GZ, Lin Q, Wu SG. Induction Camrelizumab and Modified TPF (Nab-Paclitaxel, Cisplatin, and S-1) in Locoregionally Advanced Nasopharyngeal Carcinoma. Cancer Sci. 2025;116(6):1616\u201326.","journal-title":"Cancer Sci"},{"issue":"10","key":"8865_CR22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3109\/00016489.2015.1049664","volume":"135","author":"M Hirai","year":"2015","unstructured":"Hirai M, Orita Y, Takao S, Tachibana T, Marunaka H, Makihara S, et al. How long should we continue S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck? Acta Otolaryngol. 2015;135(10):1079\u201385.","journal-title":"Acta Otolaryngol"},{"issue":"1","key":"8865_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41416-025-03033-1","volume":"133","author":"H Cheng","year":"2025","unstructured":"Cheng H, Chen J, Li Y, Li Y, Tse C, Shen B, et al. Determining the optimal duration of oral adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Br J Cancer. 2025;133(1):85\u201393.","journal-title":"Br J Cancer"},{"issue":"6","key":"8865_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","volume":"16","author":"P Blanchard","year":"2015","unstructured":"Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645\u201355.","journal-title":"Lancet Oncol"},{"issue":"1","key":"8865_CR25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1186\/s12885-022-09712-z","volume":"22","author":"Z Li","year":"2022","unstructured":"Li Z, Li C, Yang D, Song J, Liu T, Zhou Z, et al. Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis. BMC Cancer. 2022;22(1):616.","journal-title":"BMC Cancer"},{"issue":"18","key":"8865_CR26","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2025.1132","volume":"333","author":"YL Liang","year":"2025","unstructured":"Liang YL, Liu X, Shen LF, Hu GY, Zou GR, Zhang N, et al. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial. JAMA. 2025;333(18):1589\u201398.","journal-title":"JAMA"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-026-08865-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-026-08865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-026-08865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T01:20:17Z","timestamp":1786584017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12903-026-08865-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8865"],"URL":"https:\/\/doi.org\/10.1186\/s12903-026-08865-8","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Ethics Review Board of Fujian cancer hospital approved the trial (No: 2019-015-03). This trial was registered with ClinicalTrials.gov (NCT04220528) on January 4, 2020 (retrospectively registered) and performed according to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines as defined by the International Conference on Harmonization. The CONSORT guideline was used in our trial. Written informed consent was obtained from all the patients before enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1429"}}